Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU26OE)

Drug Name

PIM447 Drug Info

Synonyms

VRQXRVAKPDCRCI-ZNMIVQPWSA-N; PIM-447; 1210608-43-7; PIM447 (LGH447); N-{4-[(1r,3s,5s)-3-Amino-5-Methylcyclohexyl]pyridin-3-Yl}-6-(2,6-Difluorophenyl)-5-Fluoropyridine-2-Carboxamide; N-[4-[(1R,3S,5S)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide; UNII-9TG5O4V25H; SCHEMBL3215332; GTPL9790; 9TG5O4V25H; CHEMBL3651966; PIM 447 [WHO-DD]; BDBM106870; ZINC116907270; AKOS032945086; CS-5929; compound 8 [PMID: 26505898]; HY-19322; J3.552.648J; US8592455, 70; 5H7; 2-Pyr

Indication

Disease Entry	ICD 11	Status	REF
Myelofibrosis	2A20.2	Phase 1	[1]

Cross-matching ID

PubChem CID: 44814409
CAS Number: CAS 1210608-43-7
TTD Drug ID: DMU26OE

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Serine/threonine-protein kinase pim (PIM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SEL24	DMD37Q5	Acute myeloid leukaemia	2A60	Phase 1/2	[2]
INCB53914	DMKMSP2	Advanced malignancy	2A00-2F9Z	Phase 1/2	[1]
TP-3654	DMBQ6XY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serine/threonine-protein kinase pim (PIM)	TTA7WGU	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018 Mar 30;9(24):16917-16931.
3	Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.